Eli Lilly is readying its regulatory applications for retatrutide, following successful Phase 3 trials that demonstrated substantial weight loss and improvements in obesity-related health conditions. The drug, a "triple G" agonist, showed patients on the highest dose (12 mg) lost an average of 28.3% of their body weight, or about 70.3 pounds, over 80 weeks. A subset of patients with severe obesity who continued treatment for 104 weeks lost an average of 30.3% of their body weight, or 85 pounds. These results are considered the highest efficacy for a pharmacological weight-loss agent to date in a large pivotal trial [clinicaltrialsarena.com].
Retatrutide also delivered significant improvements in cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP). Notably, 65.3% of participants taking the 12 mg dose achieved a BMI below 30, moving them out of the obesity category, with 37.5% of those initially characterized by class 3 obesity (BMI ≥40) reaching this goal [prnewswire.com]. Beyond weight loss, the drug also showed improvements in A1C, knee osteoarthritis pain, and obstructive sleep apnea [investor.lilly.com].
While highly effective, the drug's tolerability profile has drawn some scrutiny. In the high-dose group, 11.3% of participants discontinued treatment due to adverse events, compared to 4.9% in the placebo group [clinicaltrialsarena.com]. Analysts from William Blair suggest that retatrutide's tolerability might limit its use to patients with higher BMIs, implying that Lilly's existing and highly successful drug, tirzepatide (sold as Zepbound for obesity in the US and Mounjaro internationally for both obesity and diabetes), might remain the preferred option for many due to its more balanced efficacy and tolerability. Tirzepatide generated approximately $13.5 billion from Zepbound and $2.0 billion from Mounjaro in 2025 [clinicaltrialsarena.com].
Despite potential tolerability concerns, the significant weight loss achieved, with 45.3% of patients on the 12 mg dose losing more than 30% of their body weight (an outcome often associated with weight loss surgery), positions retatrutide as a powerful contender in the obesity treatment market. The drug's broad impact on comorbidities further underscores its potential to address not just weight, but also related health complications.
Lilly is now preparing the necessary application materials for various regulatory bodies, indicating a clear path toward making this highly effective treatment option available to patients in the near future. The company anticipates a strong market presence for retatrutide, complementing its existing portfolio of diabetes and weight-loss medications.
